[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345899-105":59,"doc-detail-345899-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prostate-cancer-associated-with-muir-torre-syndrome-a-rare-case-report-and-literature-review","Prostate Cancer Associated with Muir-Torre Syndrome: A Rare Case Report and Literature Review","","Muir-Torre syndrome (MTs) is a rare autosomal dominant disorder marked by sebaceous neoplasms and internal malignancies, usually colorectal or urothelial. Prostate cancer is exceptionally uncommon in MTs, with only thirteen prior cases. This work presents a 65-year-old man with MTs due to a heterozygous MSH6 mutation and isolated loss of MSH6 expression, whose atypical course was revealed by hypermetabolic pelvic and cervical lymph nodes and confirmed metastatic prostate adenocarcinoma. Treatment with androgen deprivation and apalutamide achieved a sustained biochemical response with undetectable PSA after three years.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prostate-cancer-associated-with-muir-torre-syndrome-a-rare-case-report-and-literature-review/345899/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prostate-cancer-associated-with-muir-torre-syndrome-a-rare-case-report-and-literature-review/345899.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is prostate cancer difficult to diagnose in Muir-Torre syndrome?","Question",{"text":112,"@type":113},"The case shows that prostate biopsies and transurethral resection may be negative despite metastatic disease. The authors emphasize considering metastatic progression and maintaining a high index of suspicion in atypical presentations when MMR deficiency is suspected.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What molecular finding supported the diagnosis of Muir-Torre syndrome in this patient?",{"text":117,"@type":113},"A heterozygous MSH6 mutation was identified, alongside immunohistochemistry showing isolated loss of MSH6 protein expression with preserved microsatellite stability.",{"name":119,"@type":110,"acceptedAnswer":120},"How was the patient treated after metastatic prostate adenocarcinoma was confirmed?",{"text":121,"@type":113},"First-line androgen deprivation therapy was given using an LH-RH analog plus apalutamide, leading to a sustained biochemical response with undetectable PSA three years later.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345899,1790470974,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Case Reports in Oncology  \n\n| Case Rep Oncol 2026;19:1067–1073 |  |\n| --- | --- |\n| DOI: 10. 1159/000551667\u003Cbr>Received: September 10, 2025\u003Cbr>Accepted: February 18, 2026\u003Cbr>Published online: June 23, 2026 | © 2026 The Author(s) .\u003Cbr>Published by S. Karger AG, Basel [www.karger.com/cro](www.karger.com/cro) |\n\nThis article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ([https://karger.com/Services/OpenAccessLicense](https://karger.com/Services/OpenAccessLicense)). Usage and distribution for commercial purposes requires written permission.  \nCase Report  \nProstate Cancer Associated with Muir-Torre Syndrome: A Rare Case Report and Literature Review  \nCharles Marchand-Cretya Nicolas Jacquinb  \na Department of Radiotherapy, ICONE Cancer Center, Bezannes, France; bDepartment of Oncology, Institut Godinot, Reims, France  \nKeywords  \nMuir-Torre syndrome · Prostate cancer · Lynch syndrome · Lymph node metastases · Mismatch repair deficiency · Case report  \nAbstract  \nIntroduction: Muir-Torre syndrome (MTs) is a rare autosomal dominant disorder characterized by sebaceous neoplasms and internal malignancies, most commonly colorectal and urothelial cancers. Prostate cancer is exceptionally rare in MTs, with only thirteen cases reported to date. Case Presentation: We present the case of a 65-year-old male initially diagnosed with MTs following the development of multiple sebaceous tumorsand identification of a heterozygous MSH6 mutation. Immunohistochemistry demonstrated isolated loss of MSH6 protein expression, with preserved microsatellite stability – an unusual finding in MTs. Despite two negative prostate biopsies and a transurethral resection, choline positron emission tomography imaging revealed hypermetabolic pelvic and cervical lymph nodes. Excisional biopsy confirmed metastatic prostate adenocarcinoma (NKX3.1-positive) . The patient received first-line androgen deprivation therapy with an LH-RH analog and apalutamide, achieving a sustained biochemical response. He remained alive and on treatment with undetectable PSA 3 years later, atthe age of 74. Conclusion: This case highlights the diagnostic challenges of prostate cancer in MTs and the need to consider metastatic disease in atypical presentations, especially when MMR deficiency is suspected.  \n© 2026 The Author(s) .  \nPublished by S. KargerAG, Basel  \nCorrespondence to:  \nNicolas Jacquin, nicolas.jacquin  [reims.unicancer.fr](reims.unicancer.fr)[ ](reims.unicancer.fr)Charles Marchand-Crety, charles.marchandcrety  [gmail.com](gmail.com)  \nCase Reports in Oncology  \nCase Rep Oncol 2026;19:1067–1073 1068  \n\n| DOI: 10. 1159/000551667 | © 2026 The Author(s) . Published by S. Karger AG, Basel [www.karger.com/cro](www.karger.com/cro) |\n| --- | --- |\n\nMarchand-Crety and Jacquin: Prostate Cancer with Muir-Torre Syndrome  \nBackground  \nMuir-Torre syndrome (MTs) is a rare autosomal dominant genodermatosis characterized by the coexistence of sebaceous neoplasms and internal malignancies, most frequently colorectal and genitourinary cancers [1, 2] . It is considered a phenotypic variant of Lynch syndrome and is associated with germline mutations in DNA mismatch repair (MMR) genes, resulting in microsatellite instability (MSI) [3] . Among the MMR genes, MSH2 and MLH1 are most commonly implicated, while isolated MSH6 mutations are less frequently observed and often associated with atypical or attenuated clinical phenotypes [4] . Although colorectal and urothelial cancers are the most frequently reported malignancies in MTs, prostate cancer (PR) remains exceedingly rare in this context, with emerging evidence on the role of MMR deficiency and related molecular pathways in prostate carcinogenesis and metastatic progression [5]. To date, only thirteen cases of PR associated with MTs have been described in the literature [6–15] . We report the fourteenth documented case of PR in a patient with confirmed MTs. Notably, despite two series of p","cbCaimPw9Eo4hFNi","https://ap.wps.com/l/cbCaimPw9Eo4hFNi","pdf",2107858,"English","# Introduction\n## Case Presentation\n## Background\n## Case Presentation","[{\"question\":\"Why is prostate cancer difficult to diagnose in Muir-Torre syndrome?\",\"answer\":\"The case shows that prostate biopsies and transurethral resection may be negative despite metastatic disease. The authors emphasize considering metastatic progression and maintaining a high index of suspicion in atypical presentations when MMR deficiency is suspected.\"},{\"question\":\"What molecular finding supported the diagnosis of Muir-Torre syndrome in this patient?\",\"answer\":\"A heterozygous MSH6 mutation was identified, alongside immunohistochemistry showing isolated loss of MSH6 protein expression with preserved microsatellite stability.\"},{\"question\":\"How was the patient treated after metastatic prostate adenocarcinoma was confirmed?\",\"answer\":\"First-line androgen deprivation therapy was given using an LH-RH analog plus apalutamide, leading to a sustained biochemical response with undetectable PSA three years later.\"}]","Prostate Cancer Associated with Muir-Torre Syndrome: A Rare Case Report and Literature Review | PDF",1790059323,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31504987c035c2a3dd459aff2cfc99b0.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46e34db062fd1ad79ef20b3909fc3ff9.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96dbed6d778ccf861215a9f44e47d9d5.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/089d13155b4ddb92445e218431028a21.webp",980,1306]